Skip to main content
  • Contact
  • Login
  • Our Company
    • Our Company
    • Mission
    • Leadership
  • Clinical Studies
    • Clinical Studies
    • ECLIPSE
    • GRECO-Breast Cancer
  • Solutions
    • Solutions
    • Treatment Selection
    • Residual Disease & Recurrence Monitoring
    • Early Detection
    • Biopharma Solutions
  • International
  • Investors
    • Investors
  • Media
    • Media
    • Press Releases
    • Resources and Media Assets
    • Contacts
  • Careers
    • Careers
    • Join Our Mission
    • Jobs
Guardant Health

Press Releases

Investors Menu
  • Home
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Leadership
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017
January 30, 2023
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
January 19, 2023
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
January 17, 2023
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
January 9, 2023
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results

Quick Links

  • SEC Filings
  • Investor FAQs

IR Contact

Alex Kleban

657-254-5417
investors@guardanthealth.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Unsubscribe

Email Alert Sign Up Confirmation

REQUEST A MEETING WITH MANAGEMENT
  • Our Company
    • Mission
    • Leadership

    • International
  • Solutions
    • Treatment Selection
    • Recurrence Detection
    • Early Detection
    • Biopharma Solutions
  • Careers
    • Join Our Mission
    • Jobs
  • Investors
  • Guardant Health, Inc.

    505 Penobscot Drive
    Redwood City, CA 94063

    Telephone: 855.698.8887
    Fax: 888.974.4258

    Contact us:
    clientservices@guardanthealth.com

    Media inquiries:
    press@guardanthealth.com

© Guardant Health

CLIA # 05D2070300 | CAP Accredited # 8765297 | Terms of Use | Privacy Policy | Notice of Privacy Practices
Powered By Q4 Inc. 5.87.0.1 (opens in new window)